Indication
Triple Negative
1 clinical trial
1 product
1 drug
Clinical trial
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)Status: Recruiting, Estimated PCD: 2025-11-03
Drug
UTD1Product
Sarilumab